logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin usTools
 

News

boto imprimir
Date: 13/09/2017

A group of lymphangioleiomyomatosis (LAM) patients attend a talk on the disease and advances

David J. Kwiatkowski, a professor of medicine at Harvard University and an oncologist specializing in thoracic oncology at Dana-Farber Cancer Institute in Boston, was responsible for explaining the advances in genetics and clinical trials being conducted to combat the disease


Yesterday, a group of lymphangioleiomyomatosis (LAM) patients attended a talk in the hall Pau Viladiu of the ICO L'Hospitalet by David J. Kwiatkowski, professor of medicine at Harvard University and oncologist specialized in thoracic oncology at the Dana-Farber Cancer Institute of Boston. He explained the different advances in genetics and clinical trials that are being carryied out to fight the disease. Those attending the event were received by the director general of the ICO, Candela Calle; by the director of IDIBELL, Gabriel Capellà, and the director of the ICO-IDIBELL ProCure Program, Miguel Ángel Pujana.

 

The Spanish Association of Lymphangioleiomyomatosis (AELAM) signed an agreement with ICO in 2015 to carry out a strategic collaboration to screen new therapeutic strategies for lymphangioleiomyomatosis (LAM). In this sense  AELAM has carried out several actions with the purpose of raising funds and to be able to devote them to the investigation of the disease.

 

What is LAM?

It is a very rare lung neoplasm, of unknown cellular origin and mainly affects women, generally of childbearing age. The disease is characterized by progressive degeneration of the lungs due to invasion of metastatic cells, which may eventually require organ transplantation. It is a disease without a cure and, therefore, it is necessary to promote its research and seek solutions. That is why AELAM carries out several fundraising actions be able to support research on the disease.





foto Members of AELAM with Gabriel Capellá and Miquel Àngel Pujana (left)
Members of AELAM with Gabriel Capellá and Miquel Àngel Pujana (left)

Share/Bookmark
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell